alpidem
Ligand Summary
Alpidem shows anxiolytic and anticonvulsant properties which appear to be elicited both with a direct mechanism through the interaction with central benzodiazepine receptor (CBR) and with an indirect mechanism by the interaction with peripheral benzodiazepine receptor (PBR) as well as the stimulation of pregnenolone formation. Alpidem was briefly marketed for the treatment of anxiety, but was withdrawn because of liver toxicity.
UNII: I93SC245QZ
PubChem: 54897
ChEMBL: CHEMBL54349
DrugCentral: 134
LyCHI: 7DNR6XX8JGW2
Target Activities
4 Activities
Items per page:
1 – 4 of 4
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
---|---|---|---|---|---|---|
Ki | ||||||
IC50 | ||||||
PARTIAL AGONIST | ||||||
Ki | ||||||